1. Gleason PP, Alexander GC, Starner CI, Ritter ST, Van Houten HK, Gunderson BW, et al. Health plan utilization and costs of specialty drugs within 4 chronic conditions. J Manag Care Pharm. 2013;19(7):542–8.
2. Goldman DP, Joyce GF, Lawless G, Crown WH, Willey V. Benefit design and specialty drug use. Health Aff (Millwood). 2006;25(5):1319–31.
3. Sullivan SD. The promise of specialty pharmaceuticals: are they worth the price? J Manag Care Pharm. 2008;14(4 Suppl):S3–6.
4. Schilling B. Specialty Drug Costs Poised to Skyrocket but Many Employers Have Yet to Take Note. The Commonwealth Fund. April 11, 2012. http://www.commonwealthfund.org/publications/newsletters/purchasing-high-performance/2012/april-11-2012/featured-articles/specialty-drug-costs-poised-to-skyrocket . Accessed 5 Oct 2016.
5. Chambers JD, Thorat T, Pyo J, Chenoweth M, Neumann PJ. Despite high costs, specialty drugs may offer value for money comparable to that of traditional drugs. Health Aff (Millwood). 2014;33(10):1751–60.